Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Xavier Marechal

The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2017English

Cardiac Contractile Function and Mitochondrial Respiration in Diabetes-Related Mouse Models

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2014English

Related publications

Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor Related Diabetic Ketoacidosis

European Scientific Journal ESJ
2019English

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, With Dapagliflozin and Ipragliflozin

Pharmaceutics
Pharmaceutical Science
2020English

Protective Effects of Ipragliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, on a Non-Alcoholic Steatohepatitis Mouse Model

Yonago Acta Medica
Medicine
2019English

Clinical Risk Factors Predicting Genital Fungal Infections With Sodium–glucose Cotransporter 2 Inhibitor Treatment: The ABCD Nationwide Dapagliflozin Audit

Primary Care Diabetes
Internal MedicineNutritionEndocrinologyDieteticsMetabolismDiabetes
2018English

Ertugliflozin: A Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor for Glycemic Control in Type 2 Diabetes

Therapeutics and Clinical Risk Management
2018English

Euglycemic Diabetic Ketoacidosis Induced by Empagliflozin, Sodium-Glucose Cotransporter-2 Inhibitor, in Patient With Diabetes Mellitus Type 2 After Thoracic Surgery

Lijecnicki Vjesnik
Medicine
2020English

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin

Journal of Investigative Medicine High Impact Case Reports
RiskEpidemiologyReliabilitySafetySafety ResearchQuality
2017English

Cardiovascular Effects of Sodium Glucose Cotransporter 2 Inhibitors

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2018English

The Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin Does Not Prolong QT Interval in a Thorough QT (TQT) Study

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy